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Evidence based medicine suggest that implementations of a clinical protocol for the management of 
acute alcohol withdrawal symptoms improves patient’s outcome. Clinical guidelines were developed 
by several institutions mainly to ensure high quality, person centered, and safe management of 
alcohol withdrawal symptoms with a large variation in the local practice especially in the 
management of unplanned alcohol withdrawal with regards to the regime, choice of benzodiazepines 
and appropriate vitamin supplementation. Various health organizations advise integration of training 
for alcohol withdrawal management. Timely assessments and staff education increase patient 
monitoring, create a safer and caring environment, reduce the risks including agitation to staff and 
other patients and enhance the quality of care. This review looked at the various National Health 
Services Hospitals with guidelines and protocols providing a comprehensive review for the acute 
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Alcohol withdrawal symptoms could be elicited when patients 
are referred for admission late at night or over the weekends, 
consequently it may be inevitable to implement alcohol 
withdrawal management to avoid morbidity and possible 
mortality after ruling out other disorders1Patients should be 
treated in a Medical ward especially if the symptoms are 
severe as it will be safer2 
 
Detoxification is the treatment of symptoms and complications 
occurring after a period of heavy and sustained alcohol 
misuse3. The Goals of detoxification includes providing a safe 
withdrawal from alcohol enabling the patient to become drug 
free, providing relief of subjective symptoms, prevention of 
withdrawal complications such as Delirium Tremens (DT) and 
Korsakov’s encephalopathy, providing a humane withdrawal 
protecting the patient’s dignity and preparing for management 
of alcohol dependency4, 5  . This is a review of alcohol 
withdrawal treatment including for high risk patients such as 





Alcohol Withdrawal Symptoms  
 
Significant symptoms can be associated with the abrupt 
cessation of alcohol intake in individuals that suffer from 
alcohol dependence.  
 
The Diagnostic and Statistical Manual (DSM 5)6 Criteria for 
alcohol withdrawal requires the cessation of (or reduction in) 
heavy and prolonged alcohol use and two or more of the 
following developing within hours to a few days; automatic 
hyperactivity (ex; sweating or pulse greater than 100 beats per 
minute), increased hand tremors, Insomnia, Nausea or 
Vomiting, Transient visual, tactile or auditory hallucinations or 
illusions, psychomotor agitation, anxiety, grand mal seizures. 
The symptoms cause clinically significant distress or 
impairment in social or occupational or other important areas 
of functioning. Symptoms should not be due to a general 
medical condition and are not better accounted for by another 
mental illness.  
 
The US Preventive Services task force recommends screening 
patients for problem drinking through a careful history or 
standardized screening questionnaire for example, The 
Alcohol Used Disorders Identification, known as AUDIT is 
one assessment tool used in identification of alcohol misusers 
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Various health organizations advise 
integration of training for alcohol 
withdrawal management. 
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with a minimum score of zero and a maximum score of 40. A 
score of 8 or more is suggestive of hazardous or harmful 
alcohol consumption7 
 
Alcohol withdrawal symptoms can range from mild to severe 
symptoms: Mild symptoms may include tension, irritability, 
poor concentration, anxiety, tremors, mood and sleep 
disturbances8,9.  Moderate symptoms may include nausea, 
tremors, sweating, headache, vomiting, flu-like symptoms, 
anxiety, tachycardia, and transient auditory hallucination 9; 
while severe symptoms may include confusion, vomiting, 
visual and auditory hallucinations, delusions, aggressive 
behaviors, ataxia, seizures, altered consciousness, sweating, 
fever, tremors and dehydration 9. 
 
What is Alcoholic Hallucinosis? 
 
Alcoholic hallucinosis may develop 12 to 24 hours after 
cessation of Alcohol use. Alcoholic hallucinosis can be visual 
(for example bugs crawling on the bed), auditory (frequently 
derogatory or accusatory voices) or tactile but otherwise a 
clear sensorium, compared to Delirium Tremens where the 
sensorium is impaired 2, 10, 11. 
 
What is Alcohol withdrawal Delirium or Delirium Tremens 
(DT)? 
 
Alcohol Withdrawal Delirium or DT may develop 48 to 72 
hours after cessation of Alcohol use. DT have a mortality rate 
of 1 to 5 % and can increase to 15 to 20 % usually due to 
cardiovascular and respiratory collapse especially if 
inappropriately managed 3, 8, 10, 11. 
 
Patients with DT can present with fear, hallucinations, 
predominantly visual but may be tactile or auditory. These 
hallucinations often evoke severe fear, agitation, restlessness, 
confusion, disorientation, reversal of sleep pattern, delusions, 
paranoid ideas, increased Startle reaction, tremors in the hands 
and body, sweating, dehydration, tachycardia, increased blood 
pressure while fever (Temperature more than 38.3 C) is 
common and could be with or without infection. . DT usually 
occur in heavy drinkers who reduced their consumption or 
withdraw unexpectedly or have been inadequately treated 
during withdrawal 3, 4, 10-14.  
 
What are the risk factors for progression from mild to severe 
Alcohol withdrawal Symptoms and DT? 
 
Some factors increase the risk of progression from mild to 
severe withdrawal symptoms and DT such as fever, high 
anxiety, tachycardia especially if the heart rate is more than 
100, hypoglycemia, insomnia, sweating, hypomagnesaemia, 
hypocalcaemia, comorbid psychiatric disorders, use of other 
psychotropic drugs, marked withdrawal symptoms on 
presentation,  older Age, comorbid medical illness such as 
concurrent urinary or chest infection, abnormal liver functions, 
dehydration, hypokalemia (especially with respiratory 
alkalosis), past history of severe alcohol withdrawal, seizures 
and/or DTs, and high alcohol intake  > 15 units per day 8, 11, 14. 
 
Alcohol Related Seizures 
 
Alcohol Related Seizures are more common in patients with a 
history of multiple episodes of detoxifications and may 
develop 24 to 48 hours after cessation of alcohol use and rarely 
beyond 48 hours following cessation. They are usually 
generalized and may precede or accompany DT. Alcohol 
Related Seizures are characterized by major tonic motor 
seizures occurring during withdrawal in patients who normally 
have normal EEGs or no seizures. Fits can be single or 
generalized and 30 % are followed by DT 8, 10, 14.  
 
Wernicke’s encephalopathy (WE) and Korsakoff’s syndrome 
 
WE is characterized by a triad of confusion, ataxia (muscle 
incoordination) and ophthalmoplegia (paralysis of the ocular 
muscle). Other findings are nystagmus, hypothermia, 
hypotension and memory disturbance. High level of suspicion 
is important because not all symptoms may be present as the 
presence of only one symptom could be highly suggestive.  
WE is a complication caused by Thiamine (Vitamin B1) 
deficiency and detoxification is a risk factor. Untreated WE 
can lead to permanent brain damage, Korsakoff’s syndrome 
(characterized by antegrade amnesia, confabulation with 




Hypoglycaemia could lead to the development of acute 
confusion especially in the early stages of detoxification. The 
treatment of hypoglycemia is by administering parental 
Thiamine and glucose to prevent the precipitation of Acute 
Wernicke’s Encephalopathy, ideally done in a Medical ward or 
Emergency department 2, 16. 
 
Patients that should be admitted or referred urgently to a 
medical rather than a psychiatry ward for detox are those with 
suspected DT or past history of DT, WE, severe symptoms, 
suspected seizures or past history of seizures related to alcohol 
withdrawal, history of detox in a medical ward for severe 
alcohol withdrawal, organic complications of alcohol 
dependence such as evidence of alcoholic liver disease, 
malnutrition or nil by mouth, respiratory disease or evidence of 
other acute Medical disorder on presentation, pregnancy or 
elderly patients above 70 years or above 60 years with frailty 2, 
11, 13, 17, 18.  
Laboratory Investigations for Alcohol withdrawal patients 
 
The following tests should be carried as part of the screening 
of any suspected alcohol dependency or withdrawal;  alcohol 
breath test, FBC, U&E, LFT, GGT, Amylase, B12, folate, 
glucose, magnesium, TFT, INR, ECG, abdominal ultrasound  
10, 11, 19. 
Pharmacological Management of Alcohol withdrawal 
 
Psychopharmacology decision should be initiated depending 
on the history and objective evidence as not all patients will 
have serious withdrawal symptoms. Most inpatient alcohol 
detox should be completed in 7 to 10 days 15. The 
psychopharmacology management in alcohol withdrawal 
should ensure the suitable medication in the right dose, in the 
correct time to control the symptoms and keep the patient 




There is evidence that benzodiazepines are the treatment of 
choice to reduce alcohol withdrawal signs and symptoms, 
prevent alcohol related seizures and reduce DT 1, 8, 15, 21. Oral 
Drugs are recommended for the routine management of 
Alcohol withdrawal 19 
 
In the absence of hepatic impairment, long acting 
benzodiazepines such as chlordiazepoxide and Diazepam are 
recommended with chlordiazepoxide the treatment of choice in 
uncomplicated detoxification due to its reduced potential for 
dependency compared to Diazepam11, 14, 22. A fixed dose of 
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chlordiazoperoxide withdrawal regime should be prescribed in 
patients where it is difficult to rate their alcohol dependence 14. 
Diazepam may be an alternative in patients requiring very high 
doses due to its longer half-life. 
 
It is recommended to use one benzodiazepine and avoid using 
multiple benzodiazepines 13.Overdose of benzodiazepine can 
cause respiratory depression and mortality, while undertreating 
alcohol withdrawals could lead to DT, seizures and mortality 
13, 15.  
 
During the first 24 hours; mild symptoms that are not causing 
distress may not require medications. For mild symptoms, 
chlordiazepoxide can be prescribed when required only if 
symptoms developed but this requires more experienced staff 
for monitoring the symptoms 11, alternatively it could be 
prescribed on a fixed but reducing regime based on the clinical 
judgment.  
 
In moderate to severe withdrawal symptoms, a reducing 
regime of chlordiazepoxide over 5 to 7 days is recommended. 
Longer period of reducing regime may be needed in severe 
symptoms and up to 10 days 11. 
 
The dose is estimated by initial assessment of the predicted 
withdrawal intensity, for example, Stat Dose of 
chlordiazepoxide 20 to 50 mgs followed by 20-30 mgs QDS.  
(Lower doses could be used in mild symptoms and higher in 
moderate to severe symptoms). Additional when required 
chlordiazepoxide 10 -20 mgs QDS must be available and doses 
may be increased in more severely dependent drinkers 9, 13, 19.  
From the second to the fifth day, consider subsequent 
reduction regime by approximately 20% of the 
chlordiazepoxide dose every day. Doses of 30mg qds or above 
should only be prescribed when severe withdrawal symptoms 
expected and the patient's response to treatment must be 
regularly and closely monitored 1. 
 
Example of a reducing regime for chlordiazepoxide 11 
 
Day Dose of chlordiazepoxide 
1 20 mgs QDS 
2 15 mgs QDS 
3 10 mgs QDS 
4 10 mgs BD 
5 10 mgs OD 
 
The level of observation should Initially be every 15 minutes 
monitoring of BP, pulse, respiratory rate, pulse oximetry and 
orientation 11 for three days because of the risk of seizures and 
DT then twice daily and more frequent if needed 14, 17, 23. 
 
Respiratory rate should not be less than 10 /min and pulse 
oximetry should not be less than 90%. Doses of 
chlordiazepoxide in excess of 100mg daily can be prescribed 
in selected cases and in case of over sedation, benzodiazepines 
next dose could be missed and the regime reviewed 13. 
 
Patients with Severe Hepatic Impairment 
 
Patients with deranged liver function tests and clinical signs of 
hepatic disease should be referred to a medical unit 3. The 
metabolism of chlordiazepoxide is impaired in liver disease, 
but could be used cautiously in mild to moderate hepatic 
impairment (reduce the dose by 50%). Shorter acting 
benzodiazepines such as oxazepam or lorazepam should be 
considered as their metabolism is not impaired in liver 
disease8, 10, 14, 19.  
 
Lorazepam 0.5 mg is equivalent to chlordiazepoxide 10 mg, 
which is equivalent to diazepam 5 mgs is equivalent to 
Oxazepam 15 mgs 3, 24. 
Elderly patients 
 
To minimize the side effects of benzodiazepines in the elderly, 
start very slow and go very slow as a rule. It is recommended 
that half the dose of benzodiazepines can eventually be used 14. 
Oxazepam has a shorter half-life and less prone to toxicity and 
could be considered as an alternative to chlordiazoperoxide in 
the elderly 13, 24. 
 
What if Benzodiazepines are not suitable for the patient? 
 
Carbamazepine is an appropriate alternative to 
benzodiazepines in the treatment of alcohol withdrawal 
symptoms. It does not show significant difference in the 
adverse effects compared to benzodiazepines and its dropout 
rates are generally lower compared to benzodiazepines. 
Carbamazepine also showed a reduction in alcohol craving 
after withdrawal, is non-sedating and has less potential for 
abuse in studies up to 800 mgs of carbamazepine given in the 
first day with the dose tapered to 200 mgs by the fifth day 3, 
8,25.  
 
Clomethiazide can be used in acute alcohol withdrawal if both 
benzodiazepines and carbamazepine are contraindicated. 
Gabapentin was also shown to be effective in the treatment of 
alcohol withdrawal in small studies 8. 
 
Vitamin Supplement  
 
Oral supplementation may not be sufficient because there is 
significant impairment in the absorption of vitamins 10. 
Parental Thiamine is given in form of Intramuscular Pabrinex. 
The dose is one pair of ampoules daily for 3 to 5 days 
intramuscularly 13, 26. Pabrinex needs to be injected slowly in 
the upper lateral quadrant into the gluteal muscle, while 
varying the site of injection with repeated injections 19. 
Parenteral thiamine is associated with a low risk of 
anaphylaxis; 1 per 5 million pairs of IM ampoules used, 
consequently patients given IM Pabrinex should be closely 
monitored for 30 minutes following injection and equipment 
for anaphylaxis management should be readily available 11. 
 
Parental thiamine administration should be followed by oral 
Thiamine 100 mgs TDS, vitamin B Compound Strong Two 
tablets TDS if clinically indicated and multivitamins once 
daily 11, 13, 26. Oral Thiamine should be continued on discharge 
for 6 months if abstinence is achieved or indefinitely if heavy 
alcohol drinking continued. The daily dose of Oral Thiamine 
could be divided to optimize absorption 16, 26.  
 
Treatment of Wernicke’s consists of 2 to 3 ampoules of 
Pabrinex IV administered three times daily for at least two 
days followed by one pair for 3 to 5 days or as long as clinical 
improvement continues and it must be administered in a 
specialized medical ward after reviewing the local formulary 
13. 




Anticonvulsant prophylaxis is not recommended routinely for 
alcohol withdrawal and remains a matter of clinical judgment 
depending on the balance of risks and benefits 27. 
Carbamazepine may be the anticonvulsant of choice when 
used as a prophylaxis 5. Phenytoin must not be prescribed to 
prevent or treat alcohol withdrawal seizures 13, 16, 20, 26. 






The National Institute of Clinical Excellence in the UK 
(NICE) recommends the use of buccal Midazolam or rectal 
Diazepam 17. Some Mental Health Units use Rectal Diazepam 
10 mgs for emergency seizure control and can be repeated 
after ten minutes if the seizure continues 17. Diazepam is also 
advocated as a benzodiazepine of choice for medically assisted 
alcohol withdrawal in those with a previous history of seizures 
13, 24, while other Mental health units advocate the use of 
buccal midazolam 10 mgs, repeated after ten minutes if 
necessary for the treatment of alcohol related withdrawal 
seizures 17, 26. Continuing treatment with an anticonvulsant that 
has been used to treat alcohol withdrawal seizures is not 




Treating alcohol dependence after the treatment of withdrawal 
is good practice and acamprosate is used to maintain 
abstinence in alcohol dependence 11, 13. Treatment can be 
initiated at the time of detoxification as it may exert a 
neuroprotective effect 3. It is advised that initial prescribing 
and monitoring is arranged in secondary care for 12 weeks 
after which can be prescribed in primary care 3.  
 
Acamprosate is usually prescribed at a dose of 666 mgs three 
times daily. If the patient’s weight is less than 60 kg, the 
maximum daily dose is 1332 mgs, (666 mgs twice daily can be 
prescribed). Acamprosate should be continued for up to 12 
months or longer for those benefiting as evidence suggests that 
the benefit from Acamprosate is maintained for over one 
year11.  
 
Acamprosate should be stopped if drinking persists for 4 to 6 
weeks while taking the medication and it should be avoided in 
severe hepatic impairment or if the creatinine level is > 120 
micromole/L 13. 
 
Role for other Medications 
 
Naltrexone and Nalmefene are opioid antagonists that may 
have a role in some patients in maintaining abstinence and 
depending on the formularies available in some countries. 
However Naltrexone requires liver function tests before and 
during treatment. Nalmefene could have a role for those who 
have a high drinking risk level; ie 7.5 units of alcohol per day 
or more in men or 5 units per day or more in women. 3, 
13 Disulfiram interact with Alcohol to produce increased 
levels of acetaldyde, the accumulation of which leads to 
unpleasant symptoms such as flushing, Nausea, Vomiting, 
vertigo, headache, and abdominal pain. Consequently may not 
always be favorable by patients and may require a special 




Acute alcohol withdrawal symptoms can be unexpected and 
happens shortly after patients being admitted to the hospital 
and pharmacological management may be needed to ensure the 
safety of patients and staff. Benzodiazepines, and Thiamine 
remain the main treatment options to control the symptoms 
and prevent complications and in most cases will not be 
needed for more than 5 to 7 days. Complications of alcohol 
withdrawal include delirium, seizures, Wernicke’s 
encephalopathy and Korsakov’s. Good practice involves the 
treatment of Alcohol dependence after treating alcohol 
withdrawal with acamprosate shown to reduce craving with 
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